Rolandsson Enes Sara, Krasnodembskaya Anna D, English Karen, Dos Santos Claudia C, Weiss Daniel J
Department of Experimental Medical Science, Faculty of Medicine, Lund University, Lund, Sweden.
Wellcome-Wolfson Institute for Experimental Medicine, School of Medicine, Dentistry, and Biomedical Sciences, Queens University, Belfast, United Kingdom.
Front Pharmacol. 2021 Apr 19;12:647652. doi: 10.3389/fphar.2021.647652. eCollection 2021.
Recent advances in cell based therapies for lung diseases and critical illnesses offer significant promise. Despite encouraging preclinical results, the translation of efficacy to the clinical settings have not been successful. One of the possible reasons for this is the lack of understanding of the complex interaction between mesenchymal stromal cells (MSCs) and the host environment. Other challenges for MSC cell therapies include cell sources, dosing, disease target, donor variability, and cell product manufacturing. Here we provide an overview on advances and current issues with a focus on MSC-based cell therapies for inflammatory acute respiratory distress syndrome varieties and other inflammatory lung diseases.
基于细胞的肺部疾病和危重症治疗方法的最新进展带来了巨大希望。尽管临床前结果令人鼓舞，但将疗效转化到临床环境中尚未成功。造成这种情况的一个可能原因是对间充质基质细胞（MSC）与宿主环境之间复杂相互作用缺乏了解。MSC细胞疗法的其他挑战包括细胞来源、剂量、疾病靶点、供体变异性和细胞产品制造。在此，我们概述了相关进展和当前问题，重点关注基于MSC的细胞疗法在各种炎症性急性呼吸窘迫综合征及其他炎症性肺部疾病中的应用。
